Plasmin is the main protease to break down and dissolve thrombus.
胞浆素是消除和分解血栓的主要蛋白酶。
In this paper the best conditions of activity of plasmin were studied.
研究了赤子爱胜蚓纤溶酶活性的提高条件及酶的最适作用条件。
B. Nattokinase enhances plasmin through active pro-urokinase (endogenous).
纳豆激酶通过活性尿激酶原(内生)增强胞浆素。
Objective: To establish a assay for plasmin inhibition with the recombinant TFPI-2.
目的：建立重组TFPI-2抑制纤溶酶活性的测定方法。
We measured the plasminogen (PLG) content and plasmin (pl) activity in 54 leukemic patients.
对54例白血病患者进行血浆纤溶酶原(plg)及纤溶酶(PL)活性测定。
Objective To reveal the fibrillar network in vitreous and the effect of plasmin on this network.
目的观察玻璃体胶原纤维的空间结构及纤溶酶对其空间结构的影响。
Objective To evaluation the effect of plasmin in the treatment of Pleural Thickening by Tuberculous Pleurisy.
目的评价纤溶酶在治疗结核性胸膜炎胸膜肥厚中的效果。
This is primarily accomplished by the generation of plasmin, which breaks down fibrin and interferes with its polymerization.
这主要是通过纤维蛋白溶酶的生成，分解纤维蛋白和干扰其聚合。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
Objective To observe the clinical and fibrinolytic effect of Urokinase (UK) therapy in the acute cerebral infarction, and alteration of D-dimer concentrations and plasmin activity.
目的观察尿激酶(UK)治疗急性脑梗死的疗效及血浆纤溶酶的活性变化。
Conclusion: the study indicated that it was related to disturbance or fibrinolysis coagulation system in the patients with HAPC and plasmin capsules were valuable in prevention and treatment of HAPC.
结论：高原红细胞增多症患者存在纤溶抑制功能的亢进及凝血与纤溶系统的紊乱，溶栓胶囊对高原红细胞增多症具有明显的防治效果。
Conclusion: the study indicated that it was related to disturbance or fibrinolysis coagulation system in the patients with HAPC and plasmin capsules were valuable in prevention and treatment of HAPC.
结论：高原红细胞增多症患者存在纤溶抑制功能的亢进及凝血与纤溶系统的紊乱，溶栓胶囊对高原红细胞增多症具有明显的防治效果。
应用推荐